With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?
Global
Latest News
Advertisement
Advertisement
06 August 2009
18 August 2009
3 August 2009
Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.
16 July 2009
UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.
Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.
12 June 2009
New prediction reflects incremental pressure from economic crisis.
4 June 2009
1 June 2009
Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.
A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems.
It could be the end of the road for the UK's biotech firms if drastic action isn't taken soon.
EC proposal loosens restrictions on drug packaging and information dissemination.
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
Britain's new approach to drug pricing isn't as bad as the industry feared.
UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs
The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.
Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different"
Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service
The UK has benefited from the stem-cell debate in the US. Several scientists have fled to Europe's more favorable regulatory stance.